"Pharmacodynamics (PD) and genomic profiling of pts treated with cabiralizumab (cabira) + nivolumab (NIVO) provide evidence of on-target tumor immune modulations and support future clinical applications."

LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Pharmacodynamics (PD) and genomic profiling of pts treated with cabiralizumab (cabira) + nivolumab (NIVO) provide evidence of on-target tumor immune modulations and support future clinical applications.

3020Background: Colony stimulating factor 1 receptor (CSF-1R) signaling supports recruitment, development, and maintenance of immune suppressive macrophages within the tumor. Combining anti–CSF-1R ... Click to show full abstract

Keywords: pts treated; pharmacodynamics genomic; profiling pts; genomic profiling; treated cabiralizumab; tumor

Journal Title: Journal of Clinical Oncology
Year Published: 2018

Link to full text (if available)

Share on Social Media: Sign Up to like & get
recommendations!
0

LAUSR

You are not signed in:

Sign Up!

Related content

More Information News Social Media Video Recommended